Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81418-pharmacogenomic-multigene-drug-metabolism-panel
    Ask Trek AI about this page

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    Commercial payers pay $860 on average nationally for this procedure.

    CPT code 81418 describes a pharmacogenetic multigene panel performed on blood or saliva to detect clinically relevant variants in six or more genes that affect drug metabolism; the test must include CYP2C19 and CYP2D6 variant analysis plus CYP2D6 duplication/deletion analysis and is used to inform medication selection and dosing. Service type: genetic testing / molecular pathology. Typical site of service: clinical laboratory or outpatient specimen collection.

    For related coverage guidance, see recent payer policy updates: Oral Cancer Screening and Testing, RTM Testing for Alpha-1 Antitrypsin Deficiency, Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policy.

    Customize your policy alerts

    Sign up for cpt 81418 policy alerts

    Get alerted when payer policies referencing 81418 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    Commercial rates for CPT 81418 cluster around BUCA’s average commercial benchmark of $860.20, with notable variation across major payers. Blue Cross Blue Shield’s distribution skews higher with a median of $871.20 and a long tail to a max of $3,053.90, while Cigna and Aetna show elevated means of $852.50 and $605.20 respectively. UnitedHealth Group’s mean is lower at $729.20 and its median sits below BUCA’s average at $550.30. These contrasts indicate a market where BUCA sits near the center of commercial pricing but payers diverge meaningfully at the top end.

    Dispersion measured by the interquartile range (P75–P25) highlights where rates are tightest and widest: Aetna’s IQR is $258.00, Cigna’s IQR is $648.10, Blue Cross Blue Shield’s IQR is $270.30, BUCA’s IQR is $375.00, and UnitedHealth Group’s IQR is $535.90. Cigna exhibits the widest IQR at $648.10, reflecting the greatest mid‑range variability, while Aetna is the tightest at $258.00, indicating more concentrated commercial reimbursement around its central range.

    National Payer Mean Reimbursement Rates

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 58-year-old patient with a history of recurrent depressive disorder and poorly controlled chronic pain is scheduled for medication optimization after multiple adverse drug effects and inadequate therapeutic response. The treating oncologist and clinical pharmacist coordinate with a molecular diagnostics laboratory to perform pharmacogenomic testing on a blood specimen to evaluate variants in multiple pharmacokinetic genes, including obligatory analysis of CYP2C19 and CYP2D6 (with duplication/deletion analysis for CYP2D6). Results will inform selection and dosing of antidepressants, opioids, and other medications metabolized by these enzymes. The clinical workflow includes: pre-test counseling and informed consent; collection of a blood or saliva specimen in the clinic; test requisition with relevant clinical indication and ICD-10 code; laboratory processing with targeted genotyping or sequencing of at least six genes; result interpretation by molecular pathology; and a follow-up clinic visit where the prescribing clinician reviews actionable variants and documents medication changes in the medical record.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81225

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207ZP0102X
    207ZP0007X
    207L00000X
    261QS0132X
    2086S0127X
    207VB0002X
    163WP0809X
    163WM1400X

    Related ICD-10-CM Codes

    31 rows

    ICD-10-CM CodeDescription
    C25.4*
    C64.1*
    C64.2*
    C65.1*
    C65.2*
    C66.1*
    C66.2*
    C67.0*
    C67.1*
    C67.2*

    Showing 1–10 of 31

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Carrier Testing Panels for Genetic Diseases (for Kentucky Only)UnitedHealthcare2026-10-01
    Genetic Testing for Neurological Disorders (for Kansas Only)UnitedHealthcare2026-10-01
    Genetic and Molecular TestingProvidence Health Plan2026-10-01
    Cell-Free Fetal DNA Testing (for Idaho Only)UnitedHealthcare2026-10-01
    Next Generation Sequencing for Minimal Residual Disease DetectionProvidence Health Plan2026-10-01
    Pharmacogenetic Panel Testing (for Kansas Only)UnitedHealthcare2026-10-01
    Non-Covered Genetic Panel TestsProvidence Health Plan2026-10-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    CPT-81420-NIPS-FETAL-ANEUPLOIDY-SEQUENCING-PANEL

    CPT 81420: Cell-Free Fetal DNA Panel for Chromosomes 13, 18, 21

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    CYP2D6 gene analysis (sequence or targeted genotyping)
    Overlaps with required CYP2D6 variant analysis; may be reported when specific CYP2D6 testing is separately performed or referenced

    81479 | Unlisted molecular pathology procedure | Used when a specific proprietary panel or method lacks a direct CPT code and payer allows unlisted reporting

    0347U | Panel — pharmacogenomics (specific proprietary code) | May represent a proprietary multi-gene pharmacogenomic panel related to testing of multiple drug metabolism genes

    0348U | Pharmacogenomic panel — proprietary code | Alternative proprietary panel code potentially used by some laboratories for multi-gene pharmacogenomic testing

    0349U | Pharmacogenomic panel — proprietary code | Another proprietary panel code that may map to similar multi-gene testing workflows

    0350U | Pharmacogenomic panel — proprietary code | Additional proprietary panel code used by some laboratories

    0434U | Pharmacogenomic panel — proprietary code | Proprietary code for multi-gene pharmacogenomic assays in certain labs

    81226 | CYP2C19 gene analysis (sequence or targeted genotyping) | Corresponds to required CYP2C19 variant analysis; report when billed separately or used for cross-reference

    0070U | Pharmacogenomic panel — proprietary code | Represents another laboratory-specific multi-gene pharmacogenomic test that may map to CPT 81418 in clinical workflows